Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Psychometric Validation of the Uzbek-Language SARC-F and IPAQ-SF Among Adults With and Without Primary Hypothyroidism
This study aims to evaluate the reliability and validity of two Uzbek-language questionnaires in adults with and without primary hypothyroidism (an underactive thyroid).
The SARC-F questionnaire asks about difficulties with everyday physical activities, such as walking, standing up from a chair, and climbing stairs. It helps identify people who may need further assessment for sarcopenia, a condition involving reduced muscle strength and function. The International Physical Activity Questionnaire-Short Form (IPAQ-SF) assesses walking, moderate and vigorous physical activity, and sitting time during the previous seven days.
The study will include 480 Uzbek-speaking adults aged 18 years or older in the Andijan region of Uzbekistan. Of these, 240 will have primary hypothyroidism and 240 will have normal thyroid function. Both women and men will participate.
All participants will complete both questionnaires and undergo measurements of muscle strength and physical function. At least 200 participants will complete the same questionnaires again after 7-14 days.
The researchers will examine how consistently the questionnaires measure physical function and activity and how their results relate to objective functional measurements. No experimental treatment will be provided.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This prospective observational methodological study is designed to evaluate the measurement properties of the Uzbek-language SARC-F and International Physical Activity Questionnaire-Short Form (IPAQ-SF) among adults with and without primary hypothyroidism.
SARC-F assesses self-reported functional limitations relevant to sarcopenia screening, whereas IPAQ-SF measures self-reported physical activity. Although these instruments assess complementary aspects of physical health, they represent distinct constructs and require separate psychometric evaluation.
Participants will be recruited from outpatient healthcare facilities and the community in the Andijan region of Uzbekistan using non-probability sampling. Two clinical comparison groups will be formed: individuals with documented primary hypothyroidism, including those receiving levothyroxine, and individuals with normal thyroid function. Thyroid status will not be modified by the study.
At baseline, each participant will complete both questionnaires electronically using standardised Uzbek-language versions. Physical assessments will include handgrip dynamometry, the five-times sit-to-stand test, and a 4-m usual gait-speed test. Anthropometric measurements and relevant clinical information, including thyroid function and treatment history, will also be collected.
An embedded test-retest substudy will involve repeated administration of both questionnaires after 7-14 days. Changes in health status, treatment, mobility, and habitual physical activity will be recorded to identify clinically and behaviourally stable participants.
The primary objective is to assess the test-retest reliability of the SARC-F total score and IPAQ-SF total physical activity estimate. Secondary analyses will examine measurement error, agreement of screening and activity classifications, response distributions, and hypothesis-based construct validity using objective functional measurements. Associations between SARC-F and IPAQ-SF will also be explored without combining their scores into a composite measure.
Exploratory analyses will investigate differences in measurement properties according to thyroid status, sex, and age. Statistical analyses will follow COSMIN methodological principles and report relevant reliability estimates with 95% confidence intervals.
The study will not assess the effects of any treatment. Functional tests will support construct-validity analyses but will not serve as definitive reference standards for diagnosing sarcopenia or objectively measuring habitual physical activity.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Abdukhalim Abdurakhimov
- Numero di telefono: +998941010091
- Email: abduhalim@adti.uz
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study population will comprise Uzbek-speaking adults aged 18 years or older recruited from outpatient healthcare facilities and the community in the Andijan region of Uzbekistan. Participants will include 240 individuals with documented primary hypothyroidism and 240 euthyroid comparison participants. Both sexes will be included. All participants will complete SARC-F and IPAQ-SF, and at least 200 participants will undergo repeat questionnaire administration after 7-14 days.
Descrizione
Inclusion Criteria:
- Adults aged 18 years or older, without an upper age limit.
- Men and women who can understand and complete the Uzbek-language questionnaires.
- Ability and willingness to provide written informed consent.
- Documented primary hypothyroidism, including patients receiving levothyroxine replacement therapy, or euthyroid status without known thyroid disease and with thyroid function within the reference range.
- Willingness to complete both SARC-F and IPAQ-SF questionnaires and participate in the planned assessments.
Exclusion Criteria:
- Severe cognitive impairment or other conditions preventing reliable questionnaire completion.
- Acute severe illness at the time of assessment.
- Severe medical conditions making the planned functional tests unsafe.
- Previous participation in the preliminary SARC-F or IPAQ-SF adaptation and pilot samples used to develop the Uzbek-language versions.
- Inability or unwillingness to provide informed consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Primary Hypothyroidism
Adults aged 18 years or older with documented primary hypothyroidism, including those receiving levothyroxine replacement therapy. The planned group size is 240 participants. All participants will complete the Uzbek-language SARC-F and IPAQ-SF questionnaires and undergo standardised functional assessments. Approximately 100 participants will repeat both questionnaires after 7-14 days. |
|
Euthyroid Comparison Group
Adults aged 18 years or older without known thyroid disease and with thyroid function within the reference range. The planned group size is 240 participants. All participants will complete the Uzbek-language SARC-F and IPAQ-SF questionnaires and undergo standardised functional assessments. Approximately 100 participants will repeat both questionnaires after 7-14 days. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Test-Retest Reliability of the Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) Total Score
Lasso di tempo: Baseline and 7-14 days after baseline
|
Test-retest reliability of the Uzbek-language Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire total score (range 0-10, with higher scores indicating greater functional difficulties) will be assessed using a two-way random-effects, absolute-agreement, single-measure intraclass correlation coefficient (ICC) with a 95% confidence interval (CI). Analyses will include clinically stable participants who complete both assessments. |
Baseline and 7-14 days after baseline
|
|
Test-Retest Reliability of Total Physical Activity Measured by the International Physical Activity Questionnaire-Short Form (IPAQ-SF)
Lasso di tempo: Baseline and 7-14 days after baseline
|
Test-retest reliability of total physical activity assessed using the Uzbek-language International Physical Activity Questionnaire-Short Form (IPAQ-SF), expressed in metabolic equivalent of task minutes per week (MET-minutes/week) and transformed as log(1 + total MET-minutes/week), will be assessed using a two-way random-effects, absolute-agreement, single-measure intraclass correlation coefficient (ICC) with a 95% confidence interval (CI). Analyses will include clinically and behaviourally stable participants who complete both assessments. |
Baseline and 7-14 days after baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
SARC-F Screening Classification Agreement
Lasso di tempo: Baseline and 7-14 days after baseline
|
Agreement between positive (SARC-F score ≥4) and negative (score <4) screening classifications at the two administrations, assessed using Cohen's kappa and percentage agreement. |
Baseline and 7-14 days after baseline
|
|
IPAQ-SF Physical Activity Category Agreement
Lasso di tempo: Baseline and 7-14 days after baseline
|
Agreement between low, moderate and high physical activity categories at the two administrations, assessed using weighted kappa and percentage agreement. |
Baseline and 7-14 days after baseline
|
|
Measurement Error of the SARC-F Total Score
Lasso di tempo: Baseline and 7-14 days after baseline
|
Measurement error of the Uzbek-language Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire total score (range 0-10; higher scores indicate greater functional difficulties and worse outcomes) will be assessed using the standard error of measurement (SEM), smallest detectable change at the 95% confidence level (SDC95), and Bland-Altman limits of agreement, based on repeated assessments in clinically stable participants. |
Baseline and 7-14 days after baseline
|
|
Measurement Error of IPAQ-SF Total Physical Activity
Lasso di tempo: Baseline and 7-14 days after baseline
|
SEM, SDC95 and Bland-Altman agreement analysis, where appropriate, for repeated log(1 + total MET-minutes/week) values. Estimates on the transformed scale will be identified accordingly. |
Baseline and 7-14 days after baseline
|
|
Construct Validity of SARC-F: Handgrip Strength
Lasso di tempo: Baseline
|
Spearman correlation between baseline SARC-F total score (0-10) and handgrip strength measured by dynamometry (kg). A negative association is hypothesised. |
Baseline
|
|
Construct Validity of SARC-F: Five-Times Sit-to-Stand
Lasso di tempo: Baseline
|
Spearman correlation between baseline SARC-F total score (0-10) and five-times sit-to-stand completion time (seconds). A positive association is hypothesised. |
Baseline
|
|
Construct Validity of SARC-F: Gait Speed
Lasso di tempo: Baseline
|
Spearman correlation between baseline SARC-F total score (0-10) and usual gait speed over 4 metres (m/s). A negative association is hypothesised. |
Baseline
|
|
Construct Validity of IPAQ-SF: Gait Speed
Lasso di tempo: Baseline
|
Association between IPAQ-SF total physical activity (MET-minutes/week) and usual 4-m gait speed (m/s), assessed using Spearman correlation. A positive association is hypothesised. |
Baseline
|
|
Construct Validity of IPAQ-SF: Mobility Limitations
Lasso di tempo: Baseline
|
Association between IPAQ-SF total physical activity (MET-minutes/week) and recorded mobility limitations. Participants with mobility limitations are hypothesised to report lower physical activity. |
Baseline
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Association Between SARC-F and IPAQ-SF
Lasso di tempo: Baseline
|
Exploratory Spearman correlation between the SARC-F total score and IPAQ-SF total physical activity (MET-minutes/week). A negative association is hypothesised. |
Baseline
|
|
SARC-F Response Distribution and Internal Consistency
Lasso di tempo: Baseline
|
Distribution of total and item scores, floor and ceiling effects, corrected item-total correlations and internal consistency of the five-item SARC-F questionnaire. |
Baseline
|
|
Floor Effect of the SARC-F Total Score
Lasso di tempo: Baseline
|
Percentage of participants obtaining the minimum possible total score of 0 on the Uzbek-language Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire (range 0-10; higher scores indicate greater functional difficulties). The floor effect will be reported as a percentage. |
Baseline
|
|
Ceiling Effect of the SARC-F Total Score
Lasso di tempo: Baseline
|
Percentage of participants obtaining the maximum possible total score of 10 on the Uzbek-language Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire (range 0-10; higher scores indicate greater functional difficulties). The ceiling effect will be reported as a percentage. |
Baseline
|
|
Distribution of the SARC-F Total Score
Lasso di tempo: Baseline
|
Baseline total score of the Uzbek-language Strength, Assistance in Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire, ranging from 0 to 10 points. Higher scores indicate greater functional difficulties. The distribution will be described using the median and interquartile range. |
Baseline
|
|
Total Physical Activity Measured by IPAQ-SF
Lasso di tempo: Baseline
|
Total physical activity will be assessed using the Uzbek-language International Physical Activity Questionnaire-Short Form (IPAQ-SF). Weekly physical activity will be calculated from walking, moderate-intensity and vigorous-intensity activities according to the IPAQ-SF scoring protocol and expressed in metabolic equivalent of task minutes per week (MET-minutes/week). Higher values indicate greater reported physical activity. The measure has no fixed maximum score. |
Baseline
|
|
IPAQ-SF Physical Activity Categories
Lasso di tempo: Baseline
|
Physical activity will be classified as low, moderate or high using the established scoring criteria of the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The number and percentage of participants in each category will be reported. Categories reflect increasing levels of reported physical activity. |
Baseline
|
|
Sitting Time Measured by IPAQ-SF
Lasso di tempo: Baseline
|
Self-reported sitting time during a usual weekday over the preceding seven days will be assessed using the sitting item of the Uzbek-language International Physical Activity Questionnaire-Short Form (IPAQ-SF). Sitting time will be expressed in minutes per day. Higher values indicate longer sedentary time. Valid values range from 0 to 1,440 minutes per day. |
Baseline
|
|
Invalid or Implausible IPAQ-SF Responses
Lasso di tempo: Baseline
|
The percentage of participants with invalid or implausible baseline responses to the Uzbek-language International Physical Activity Questionnaire-Short Form (IPAQ-SF) will be determined using prespecified data-cleaning and scoring rules. Each participant will be classified as having either valid or invalid/implausible responses. The outcome will be reported as the percentage of participants classified as invalid/implausible. |
Baseline
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Abdukhalim Abdurakhimov, PhD, Andijan State Medical Institute, Andijan 170127
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del sistema endocrino
- Malattie del sistema nervoso
- Manifestazioni neuromuscolari
- Condizioni patologiche, anatomiche
- Atrofia muscolare
- Atrofia
- Malattie della tiroide
- Condizioni patologiche, segni e sintomi
- Comportamento
- Segni e sintomi
- Sarcopenia
- Ipotiroidismo
- Attività motoria
Altri numeri di identificazione dello studio
- UZ-SARCF-IPAQ-2026
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .